JNJ-63576253 is a clinical-stage small molecule androgen receptor (AR) antagonist active against both wild-type and F877L-mutant forms, targeting castration-resistant prostate cancer (mCRPC). It is utilized in preclinical research to investigate AR signaling and resistance mechanisms in relevant in vitro and in vivo models.